---
title: HCA Healthcare (HCA)
layout: default
nav_order: 182
---

# HCA Healthcare
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $63 billion

HCA Healthcare operates a network of hospitals and surgical centers across the United States and the United Kingdom.  The company derives most of its revenue from providing health care services through these facilities.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=HCA+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/HCA/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat Analysis (3/5):**

HCA possesses a *narrow moat*, primarily stemming from *economies of scale* and *switching costs*.  

* **Economies of scale:**  As the largest hospital operator in many of its markets, HCA benefits from cost advantages related to purchasing, administration, and negotiating leverage with payers.  This is a key element in today’s cost-conscious health care environment. As the Q2 2024 earnings call revealed, the company continues to improve care coordination across hospitals, benefiting from their vast network. Scale becomes even more valuable as the health care industry consolidates, which enables HCA to offer a wider array of services and leverage its fixed costs (labor, property, and equipment) across a larger revenue base.

* **Switching Costs:** While individual patient switching costs are minimal, hospitals and physicians have higher switching costs with HCA because of the integration into their networks and systems.  Relationships with doctors, referral networks, and established reputations within communities further enhance this stickiness. The Q3 2023 earnings call highlighted the importance of HCA’s network in attracting and retaining physicians, reinforcing this aspect of the moat.

{: .warning }

However, the moat is not unassailable.  Competition remains intense, especially from other large, regional, and not-for-profit health care systems. Also, government policy and regulatory changes continually pressure pricing. The ongoing shift to outpatient care and increased consumer power continue to create margin pressure.  HCA’s moat, while real, is narrow and needs constant vigilance to maintain.
{: }

**Management Assessment (3/5):**

HCA's management receives a moderate rating.  

* **Positives:**  The company has shown a long-term commitment to shareholder value, generating excess returns on capital and steady dividend growth. The management team appears competent and capable and has deep knowledge of the health care industry. They communicate clearly about current challenges and long-term opportunities. The Q2 2023 earnings call highlighted their disciplined approach to capital allocation, including debt reduction and investment in strategic growth initiatives. They demonstrate some owner mentality through insider ownership and a commitment to share buybacks.

* **Negatives:** Management's compensation is high, but not excessive relative to peers. Compensation does appear partly tied to earnings growth, though, which can encourage short-term focus. As the Q1 2023 earnings call revealed, stock buybacks have been aggressively used, which, while beneficial in the current environment, might become problematic if HCA is overpaying for shares. Overall, management’s capital allocation decisions seem rational, but hardly exceptional, with heavy acquisitions at hefty prices.

{: .important }

The management team seems to understand the importance of cost efficiency and balancing growth, and they effectively leverage their hospital network to grow and expand market share. Yet their apparent prioritization of share repurchases raises concerns about potential misallocation of capital, and their willingness to pay premium prices in acquisitions does give one pause, especially when combined with the narrowness of their moat.
{: }

**Catalyst (2/5):**

HCA’s catalyst rating is modest.

* **Potential Positive Catalysts:** The health care industry is expected to continue its consolidation, presenting acquisition opportunities for scale players like HCA.  Increasing demand for health care services, driven by demographic trends and medical innovation, should provide a long-term tailwind.  The company's efforts to improve operating efficiency and cost management, as highlighted in the Q3 2023 earnings call, could lead to margin expansion and earnings growth. The company continues to invest in its facilities and network; the potential benefits of these investments might become apparent in the future, as mentioned in the Q2 2024 earnings call.

* **Potential Negative Catalysts:**  Regulatory pressures, government policy, and competition could limit pricing power and compress margins.  Further industry consolidation could lead to overpaying for acquisitions. A sharp rise in interest rates would affect debt service costs and put pressure on profitability.

{: .note }

Overall, while the catalysts are not nonexistent, they are not overwhelmingly strong. Industry consolidation is a double-edged sword, and the regulatory environment remains challenging.
{: }


**Valuation ($63 billion):**

A discounted cash flow (DCF) valuation was conducted using enterprise DCF to value HCA.  

* **Assumptions:** Revenue growth based on the latest revenue guidance of 3-4% and organic growth from 2024 onward; stable operating margins over time; capital expenditures at 5% of revenues, consistent with historical averages; capital structure at 15% debt and 85% equity (to reflect lower debt/equity trend), derived by a two-year average of market value of debt and market value of equity; Cost of equity derived from bond rating for additional insight on debt structure decisions; probability of failure set at 10% (conservative), and loss given failure set at 25% (conservative).

* **Calculations:**

1. **Forecast Revenue, Margins, and Free Cash Flows:** Projected income statement, balance sheet, and cash flow statement for next ten years based on growth and margin assumptions.

2. **Calculate Return on Invested Capital (ROIC):** ROIC computed each year based on adjusted operating income and invested capital.

3. **Estimate Cost of Capital:**  Risk-free rate (3%), equity risk premium (4.5%), beta (1.3) (average for previous few years), marginal tax rate (21%), and cost of debt (4.8%) (using a synthetic bond rating for their blended interest rate from 10-year HCA bonds, reflecting their debt risk). From these inputs, cost of capital is computed as:

   Cost of Capital = (0.048)(0.15)(1-0.21) + (0.077)(0.85) = 0.071, or 7.1%.

4. **Calculate Terminal Value:**  A conservative approach was used, and so we assume no growth in the terminal value. Terminal value is derived with the constant perpetuity formula as:
   
   Terminal Value = (After-tax operating income in year 11)/(Cost of Capital) = 3.325/0.071 = 46.8 billion.

5. **Discount Cash Flows and Terminal Value:** Discounted the free cash flows for next ten years and the terminal value at the cost of capital, resulting in a present value for the operating assets.

6. **Calculate Enterprise Value:** Added excess cash and marketable securities from the balance sheet to the value of operating assets.

7. **Calculate Equity Value:** Subtracted debt and debt equivalents from the enterprise value.

{: .highlight }
8. **Calculate Value per Share:** Divided the equity value by the number of diluted shares outstanding (from the latest earnings release), and multiplied by the market price of health care basket. This approach yielded a fair value of approximately $63 billion. {: }

{: .note }

**Recent Concerns/Controversies:** The health care industry is facing pressure from numerous government regulations as well as the ongoing transition of hospitals into outpatient centers for some procedures. As mentioned in the Q2 2024 earnings call, this will necessitate some investments and restructuring.
{: }

**Key Risks to Valuation:**

* **Growth:** Achieving the assumed revenue growth rate of 3-4% is not guaranteed, given intense competition.
* **Margins:** Margin compression could occur due to pricing pressures and rising labor costs.
* **Regulations:** Changes in government regulations or insurance reimbursements could negatively affect earnings.
* **Acquisitions:** Overpaying for acquisitions could erode shareholder value, as mentioned in Michael Burry's article on buying and selling in 2000.


This valuation is based on several years of HCA’s financial data and information, and reflects a reasonably pessimistic and skeptical outlook. Given their performance, moat, and the risks they face, this valuation seems reasonable to a value investor looking for a margin of safety, though the stock may not be an immediate “buy” if the price is not at a significant discount to fair value.